Robberecht W, Andries M, Denef C
Laboratory of Cell Pharmacology, University of Leuven, School of Medicine, Belgium.
Neuroendocrinology. 1992 Aug;56(2):185-94. doi: 10.1159/000126227.
In aggregate cell cultures of 15- to 20-day-old rat pituitary maintained in serum-free medium, luteinizing hormone-releasing hormone (LHRH) (10 nM) stimulated prolactin (PRL) release, confirming our previous results and those of others with serum-supplemented medium. Since angiotensin II (AII) stimulates PRL release and a renin-angiotensin system is expressed in gonadotrophs, LHRH stimulation of PRL release might be mediated by AII. To evaluate this hypothesis, the influence of (Sar1,Ala8)AII and (Sar1,Ile8)AII two peptide AII receptor antagonists, of DUP753, a nonpeptide and stable AII receptor antagonist, of a converting enzyme inhibitor, and of angiotensinogen on LHRH-induced PRL release was tested in various in vitro conditions of 15- to 20-day-old female rat pituitary. In aggregates maintained in serum-free medium with or without dexamethasone (DEX) and triiodothyronine (T3), or maintained in serum-supplemented medium, the effect of LHRH on PRL release was not affected by (Sar1Ala8)AII (0.1 microM), (Sar1,Ile8)AII (10 microM) or DUP753 (10 microM). Only a high dose (10 microM) of (Sar1,Ala8)AII attenuated the LHRH-induced PRL release. The latter attenuation was seen only with aggregates cultured in the DEX/T3 medium and not with aggregates cultured in the presence of serum. A dose of 1 or 10 nM (Sar1,Ala8)AII also failed to block the effect of LHRH used at 1 nM. In contrast, (Sar1,Ala8)AII dose dependently as well as DUP753 (10 microM) abolished the AII-induced PRL release. (Sar1,Ala8)AII also failed to affect the LHRH-induced PRL release in pituitary cell aggregates from 6-week-old male rats. However, in aggregates from both immature and 6-week-old rats, (Sar1,Ala8)AII provoked a small and statistically significant attenuation of the LHRH-induced PRL release when a 100 nM dose of LHRH was used. In freshly isolated hemipituitaries from 5-day-old rats, (Sar1,Ala8)AII (1 or 10 microM) did not affect the LHRH- (10 nM) induced PRL release. In single cells obtained by redispersion of aggregates and mounted in a Biogel P2 column, LHRH still stimulated PRL release. Again this effect could not be blocked by DUP753. Treatment of aggregate cell cultures with the angiotensin-converting enzyme inhibitor captopril or with angiotensinogen did not alter the LHRH-induced PRL release. It is concluded that AII is not the paracrine factor mediating the effect of LHRH at low nanomolar doses on PRL release, at least not through the classical AII receptor. The involvement of AII acting on a non-(Sar1,Ala8)AII-sensitive receptor cannot be excluded and warrants further investigation.
在无血清培养基中培养的15至20日龄大鼠垂体的聚合细胞培养物中,促黄体生成激素释放激素(LHRH)(10 nM)刺激催乳素(PRL)释放,证实了我们之前的结果以及其他人在添加血清的培养基中的结果。由于血管紧张素II(AII)刺激PRL释放且促性腺激素细胞中表达肾素-血管紧张素系统,LHRH对PRL释放的刺激可能由AII介导。为评估该假设,在15至20日龄雌性大鼠垂体的各种体外条件下,测试了两种肽类AII受体拮抗剂(Sar1,Ala8)AII和(Sar1,Ile8)AII、一种非肽类且稳定的AII受体拮抗剂DUP753、一种转化酶抑制剂以及血管紧张素原对LHRH诱导的PRL释放的影响。在添加或不添加地塞米松(DEX)和三碘甲状腺原氨酸(T3)的无血清培养基中培养的聚集体,或在添加血清的培养基中培养的聚集体中,LHRH对PRL释放的作用不受(Sar1Ala8)AII(0.1 microM)、(Sar1,Ile8)AII(10 microM)或DUP753(10 microM)的影响。只有高剂量(10 microM)的(Sar1,Ala8)AII减弱了LHRH诱导的PRL释放。后者的减弱仅在DEX/T3培养基中培养的聚集体中可见,而在有血清存在的情况下培养的聚集体中未见。1或10 nM剂量的(Sar1,Ala8)AII也未能阻断1 nM LHRH的作用。相反,(Sar1,Ala8)AII剂量依赖性地以及DUP753(10 microM)消除了AII诱导的PRL释放。(Sar1,Ala8)AII也未影响6周龄雄性大鼠垂体细胞聚集体中LHRH诱导的PRL释放。然而,在未成熟大鼠和6周龄大鼠的聚集体中,当使用100 nM剂量的LHRH时,(Sar1,Ala8)AII引起LHRH诱导的PRL释放有轻微且具有统计学意义的减弱。在5日龄大鼠新鲜分离的半垂体中,(Sar1,Ala8)AII(1或10 microM)不影响LHRH(10 nM)诱导的PRL释放。在通过聚集体重新分散获得并安装在Biogel P2柱中的单细胞中,LHRH仍刺激PRL释放。同样,这种作用不能被DUP753阻断。用血管紧张素转化酶抑制剂卡托普利或血管紧张素原处理聚集体细胞培养物不会改变LHRH诱导的PRL释放。结论是,AII不是介导低纳摩尔剂量LHRH对PRL释放作用的旁分泌因子,至少不是通过经典的AII受体。不能排除AII作用于非(Sar1,Ala8)AII敏感受体的情况,值得进一步研究。